Janux Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Janux Therapeutics Free Cash Flow (FCF) History (JANX)
Janux Therapeutics reported −$83.3M in free cash flow for fiscal 2025, a decrease of $39.1M from the previous fiscal year, with a free cash flow margin of −832.78%.
View full Janux Therapeutics company overviewJanux Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$83.3M | −$39.1M | — | −832.78% |
| 2024 | 2024-12-31 | −$44.2M | $8.3M | — | −417.20% |
| 2023 | 2023-12-31 | −$52.4M | −$3.1M | — | −648.58% |
| 2022 | 2022-12-31 | −$49.4M | −$30.9M | — | −573.24% |
| 2021 | 2021-12-31 | −$18.5M | −$14.1M | — | −507.51% |
| 2020 | 2020-12-31 | −$4.4M | — | — | — |
Janux Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.3M | $36.6M | — | +119.63% |
| Q1 2026 | 2026-03-31 | −$12.6M | $4.8M | — | −337.80% |
| Q4 2025 | 2025-12-31 | −$28.6M | −$11.9M | — | — |
| Q3 2025 | 2025-09-30 | −$12.9M | −$10.7M | — | −129.49% |
| Q2 2025 | 2025-06-30 | −$24.3M | −$14.2M | — | — |
| Q1 2025 | 2025-03-31 | −$17.4M | −$2.4M | — | — |
| Q4 2024 | 2024-12-31 | −$16.8M | −$6.4M | — | — |
| Q3 2024 | 2024-09-30 | −$2.3M | $9.9M | — | −513.90% |
| Q2 2024 | 2024-06-30 | −$10.1M | $5.5M | — | −113.70% |
| Q1 2024 | 2024-03-31 | −$15.0M | −$838,000 | — | −1200.80% |
| Q4 2023 | 2023-12-31 | −$10.4M | $3.6M | — | −423.24% |
| Q3 2023 | 2023-09-30 | −$12.2M | $3.8M | — | −483.87% |
| Q2 2023 | 2023-06-30 | −$15.6M | −$8.7M | — | −1479.09% |
| Q1 2023 | 2023-03-31 | −$14.2M | −$1.7M | — | −693.16% |
| Q4 2022 | 2022-12-31 | −$14.0M | −$2.3M | — | −491.00% |
| Q3 2022 | 2022-09-30 | −$15.9M | −$10.0M | — | −878.87% |
| Q2 2022 | 2022-06-30 | −$7.0M | −$688,000 | — | −294.76% |
| Q1 2022 | 2022-03-31 | −$12.5M | −$17.9M | — | −786.22% |
| Q4 2021 | 2021-12-31 | −$11.7M | −$10.6M | — | −721.16% |
| Q3 2021 | 2021-09-30 | −$5.9M | — | — | −511.73% |
| Q2 2021 | 2021-06-30 | −$6.3M | — | — | −1303.53% |
| Q1 2021 | 2021-03-31 | $5.4M | — | — | +1423.68% |
| Q3 2020 | 2020-09-30 | −$1.1M | — | — | — |
Janux Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$4.4M to −$83.3M, a net decrease of $78.9M. Janux Therapeutics's latest reported quarter, Q2 2026, generated $12.3M in free cash flow, an increase of $36.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Janux Therapeutics filings at SEC.gov ↗